Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 3
2022 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Targeting FGFRs Using PD173074 as a Novel Therapeutic Strategy in Cholangiocarcinoma.
Balasubramanian B, Yacqub-Usman K, Venkatraman S, Myint KZ, Juengsamarn J, Sarkhampee P, Lertsawatvicha N, Sripa J, Kuakpaetoon T, Suriyonplengsaeng C, Wongprasert K, Grabowska AM, Bates DO, Janvilisri T, Tohtong R. Balasubramanian B, et al. Among authors: venkatraman s. Cancers (Basel). 2023 Apr 28;15(9):2528. doi: 10.3390/cancers15092528. Cancers (Basel). 2023. PMID: 37173994 Free PMC article.
Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma.
Balasubramanian B, Venkatraman S, Myint KZ, Janvilisri T, Wongprasert K, Kumkate S, Bates DO, Tohtong R. Balasubramanian B, et al. Among authors: venkatraman s. Pharmaceuticals (Basel). 2021 Jan 11;14(1):51. doi: 10.3390/ph14010051. Pharmaceuticals (Basel). 2021. PMID: 33440754 Free PMC article. Review.
Upregulated LAMA3 modulates proliferation, adhesion, migration and epithelial‑to‑mesenchymal transition of cholangiocarcinoma cells.
Islam K, Balasubramanian B, Venkatraman S, Thummarati P, Tunganuntarat J, Phueakphud N, Kanjanasirirat P, Khumpanied T, Kongpracha P, Kittirat Y, Tohtong R, Janvilisri T, Wongtrakoongate P, Borwornpinyo S, Namwat N, Suthiphongchai T. Islam K, et al. Among authors: venkatraman s. Sci Rep. 2023 Dec 18;13(1):22598. doi: 10.1038/s41598-023-48798-8. Sci Rep. 2023. PMID: 38114514 Free PMC article.
Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma.
Myint KZ, Sueca-Comes M, Collier P, Balasubramanian B, Venkatraman S, Gordan J, Zaitoun AM, Mukherjee A, Arora A, Larbcharoensub N, Suriyonplengsaeng C, Wongprasert K, Janvilisri T, Gomez D, Grabowska AM, Tohtong R, Bates DO, Yacqub-Usman K. Myint KZ, et al. Among authors: venkatraman s. Front Oncol. 2023 Dec 7;13:1184900. doi: 10.3389/fonc.2023.1184900. eCollection 2023. Front Oncol. 2023. PMID: 38144528 Free PMC article.
Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation.
Myint KZ, Balasubramanian B, Venkatraman S, Phimsen S, Sripramote S, Jantra J, Choeiphuk C, Mingphruedhi S, Muangkaew P, Rungsakulkij N, Tangtawee P, Suragul W, Farquharson WV, Wongprasert K, Chutipongtanate S, Sanvarinda P, Ponpuak M, Poungvarin N, Janvilisri T, Suthiphongchai T, Yacqub-Usman K, Grabowska AM, Bates DO, Tohtong R. Myint KZ, et al. Among authors: venkatraman s. Pharmaceuticals (Basel). 2024 Feb 2;17(2):197. doi: 10.3390/ph17020197. Pharmaceuticals (Basel). 2024. PMID: 38399413 Free PMC article.
Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells.
Boonsri B, Yacqub-Usman K, Thintharua P, Myint KZ, Sae-Lao T, Collier P, Suriyonplengsaeng C, Larbcharoensub N, Balasubramanian B, Venkatraman S, Egbuniwe IU, Gomez D, Mukherjee A, Kumkate S, Janvilisri T, Zaitoun AM, Kuakpaetoon T, Tohtong R, Grabowska AM, Bates DO, Wongprasert K. Boonsri B, et al. Among authors: venkatraman s. Cancer Res Treat. 2021 Apr;53(2):457-470. doi: 10.4143/crt.2020.585. Epub 2020 Oct 7. Cancer Res Treat. 2021. PMID: 33070556 Free PMC article.
11 results